DVYSR Share Price Performance
SEK 96.50
-3.70 (-3.69%)
38.2% undervalued intrinsic discount
SEK 156.12
Fair Value
Price SEK 96.50
AnalystConsensusTarget SEK 156.12
Fair ValueSEK 156.12
Share Pricen/a
Analysis Article • May 04
Devyser Diagnostics AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
DVYSR Community Narratives
AN
Fair Value
·Fair Value SEK 156.12 38.2% undervalued intrinsic discount
Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position
Catalysts About Devyser Diagnostics Devyser Diagnostics develops and commercializes specialized genetic testing solutions for transplantation and hereditary diseases, with a growing footprint in regulated clinical markets. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 156.12
38.2% undervalued intrinsic discount
Fair Value
Profit Margin
28.99%
Future PE
17.59x
Price in 2028
SEK 181.67
Trending Discussion
Recently Updated Narratives
AN
Transplant And Prenatal Testing Expansion Will Drive Strong Long Term Market Position
Fair Value: SEK 156.12 38.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Devyser Diagnostics AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 20, 2026
- 0.89
- 80.27%
- 5.83%
- 0.08%
About DVYSR
- Founded
- 2004
- Employees
- 110
- CEO
- WebsiteView website
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.
